Related Experiment Video
Updated: Aug 12, 2026
10:30
Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
Published on: January 25, 2017
1992 Stohlman Memorial Lecture: targeting the IL-2 receptor
1Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Leukemia
|August 1, 1993
Summary
Interleukin-2 receptor (IL-2R)-directed therapy shows promise for treating adult T-cell leukemia (ATL). Humanized anti-Tac antibodies, armed with toxins or radionuclides, achieved significant remission rates in ATL patients with minimal toxicity.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Human T-cell lymphotropic virus I (HTLV-I)-associated leukemia/lymphoma (ATL) is a challenging malignancy.
- Interleukin-2 receptor (IL-2R) is differentially expressed on normal and malignant cells, presenting a therapeutic target.
Purpose of the Study:
- To evaluate the efficacy and safety of IL-2R-directed therapies for ATL.
- To develop improved anti-IL-2R monoclonal antibodies with enhanced effector functions.
Main Methods:
- Treatment of ATL patients with unmodified anti-Tac monoclonal antibody.
- Development and use of humanized anti-Tac antibodies with improved pharmacokinetics and antibody-dependent cellular cytotoxicity (ADCC).
- Clinical trial using 90Y-labeled anti-Tac (90Y-anti-Tac) in ATL patients.
Main Results:
- Unmodified anti-Tac resulted in remission in one-third of ATL patients.
- Humanized anti-Tac demonstrated reduced immunogenicity and enhanced ADCC.
- 90Y-anti-Tac therapy led to sustained partial or complete remission in 10 out of 15 ATL patients.
Conclusions:
- IL-2R-directed therapy, particularly with humanized anti-Tac and radionuclide conjugates, offers a new therapeutic strategy for ATL.
- This approach holds potential for treating graft-versus-host disease, allograft rejection, autoimmune disorders, and leukemia/lymphoma.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:15Activation of Integrins
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
01:31Immunoglobulin-like Cell Adhesion Molecules
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
01:29The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...